4/A//SEC Filing
BALL KRISTINE M 4/A
Accession 0000899243-19-029293
CIK 0001566044other
Filed
Dec 15, 7:00 PM ET
Accepted
Dec 16, 5:14 PM ET
Size
9.7 KB
Accession
0000899243-19-029293
Insider Transaction Report
Form 4/AAmended
BALL KRISTINE M
SVP, Corporate Strategy & CFO
Transactions
- Tax Payment
Common stock
2019-12-11$4.52/sh−27,766$125,502→ 52,534 total - Exercise/Conversion
Restricted Stock Units
2019-12-11−80,300→ 0 total→ Common Stock (80,300 underlying) - Exercise/Conversion
Common stock
2019-12-11+80,300→ 80,300 total
Footnotes (1)
- [F1]On July 29, 2019, the Reporting Person was granted 80,300 restricted stock units ("RSUs"), for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs were scheduled to vest in two (2) equal annual installments beginning July 29, 2020. The vesting of the RSUs was accelerated in full on December 11, 2019 in connection with the pending transactions contemplated by the Agreement and Plan of Merger entered into on November 10, 2019 among the Issuer, Foamix Pharmaceuticals Ltd and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of the Issuer, in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code.
Documents
Issuer
Menlo Therapeutics Inc.
CIK 0001566044
Entity typeother
Related Parties
1- filerCIK 0001266163
Filing Metadata
- Form type
- 4/A
- Filed
- Dec 15, 7:00 PM ET
- Accepted
- Dec 16, 5:14 PM ET
- Size
- 9.7 KB